Tag: Astellas

Cell and Gene Therapy, Industry

Astellas adds to ‘off-the-shelf’ cell therapy capabilities with Poseida deal

May 1, 2024

Via: Biopharma Dive

Astellas Pharma is betting again on cell therapy, announcing Wednesday a deal with Poseida Therapeutics to develop donor-derived treatments for cancer. Through the partnership, the companies aim to create two allogeneic, or “off-the-shelf,” cell therapies for solid tumors. Astellas will […]

Cell and Gene Therapy, Industry

Astellas invests $50m to support advancement of Poseida’s cancer cell therapy

August 8, 2023


Under the terms of the agreement, Astellas will invest a total of $50m, including $25m to acquire 8,333,333 in shares of the common stock of Poseida, as well as a one-time $25m payment for a right of exclusive negotiation and […]

Mergers and Acquisitions

Astellas to acquire eye drug developer Iveric Bio for $5.9B

May 1, 2023

Via: Biopharma Dive

Japanese drugmaker Astellas Pharma on Sunday agreed to acquire Iveric Bio for about $5.9 billion, betting that a medicine the biotechnology company has developed for a common type of vision loss can help it build an eye drug business. Astellas […]

Cell and Gene Therapy, FDA, Industry, Regulations

FDA lifts hold on Astellas’ Pompe gene therapy

January 20, 2023

Via: Pharmaphorum

The US regulator placed a hold on clinical testing of the gene therapy last June, shortly after a serious case of peripheral sensory neuropathy was reported in the phase 1/2 FORTIS trial in late-onset Pompe disease (LOPD). That came amid […]

Cell and Gene Therapy, Industry

Astellas licenses companion drug for Pompe gene therapy

January 10, 2023

Via: Pharmaphorum

The exclusive deal – which includes an upfront payment of $10 million and up to $340 million in milestone payments at the back end – covers the use of Selecta’s immunoglobulin G (IgG) protease drug IdeXork (Xork) alongside Astellas’ AT845, […]

Cell and Gene Therapy, Industry, Mergers and Acquisitions

Astellas to support development of Taysha’s AAV-based gene therapy programmes

October 26, 2022


Under the terms of the agreement, the Japanese firm will invest a total of $50m to acquire 15% of the outstanding common stock of Taysha and to receive an exclusive option to license two of Taysha’s clinical stage programmes: TSHA-102 […]

Cell and Gene Therapy, Industry, Mergers and Acquisitions

Astellas makes another gene therapy play, takes stake in Taysha

October 25, 2022

Via: Pharmaphorum

The Japanese firm has agreed to make a $50 million investment in Dallas-based Taysha in exchange for a 15% stake in the company, plus exclusive options to license two clinical-stage, single-gene therapies for rare genetic diseases. The option covers TSHA-102, […]

Cell and Gene Therapy, Industry

Astellas and Dyno Therapeutics to develop AAV gene therapy vectors

December 6, 2021

Via: European Pharmaceutical Review

Astellas Pharma and Dyno Therapeutics have announced an option and license agreement to develop next-generation adeno-associated virus (AAV) vectors for gene therapy directed to skeletal and cardiac muscle using Dyno’s CapsidMap™ platform. Dyno’s CapsidMap platform represents a new approach applying […]

Cell and Gene Therapy, Industry

Dyno attracts $1.6bn gene therapy deal with Astellas

December 2, 2021

Via: Pharmaphorum

The Japanese drugmaker is paying $18 million upfront to exercise an option on the AAV platform – which my help avoid safety issues that have emerged with other AAV-based gene therapies – with milestone and royalty payments that could exceed […]

Cell and Gene Therapy, Industry

More trouble for Astellas as AT132 gene therapy trial is halted again

September 1, 2021

Via: Pharmaphorum

The ASPIRO trial of AT132 has been paused after abnormal liver function tests (LFTs) were seen in a patient receiving the gene therapy, and information on the adverse event has been shared with regulators, according to the drugmaker. ASPIRO was […]

Manufacturing, Mergers and Acquisitions, Research and Development

Astellas, CytomX Launch $1.7B Cancer Immunotherapy Collaboration

March 24, 2020

Via: Genetic Engineering and Biotechnology News

Astellas Pharma plans to expand its pipeline of next-gen immuno-oncology treatments through a collaboration with CytomX that could generate more than $1.68 billion for the South San Francisco, CA, developer of antibody therapeutics. Through the collaboration, announced Monday night, Astellas […]